|
US6936694B1
(en)
|
1982-05-06 |
2005-08-30 |
Intermune, Inc. |
Manufacture and expression of large structural genes
|
|
ES2055445T3
(es)
|
1989-08-22 |
1994-08-16 |
Immunex Corp |
Proteinas de fusion que comprenden gm-csf e il-3.
|
|
US6277969B1
(en)
|
1991-03-18 |
2001-08-21 |
New York University |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
|
US5914254A
(en)
|
1993-08-02 |
1999-06-22 |
Celtrix Pharmaceuticals, Inc. |
Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
|
|
SI1121382T1
(sl)
|
1998-10-16 |
2007-02-28 |
Biogen Idec Inc |
Fuzijski proteini interferona-beta in uporabe
|
|
US7101974B2
(en)
|
2000-03-02 |
2006-09-05 |
Xencor |
TNF-αvariants
|
|
US20020193569A1
(en)
|
2001-06-04 |
2002-12-19 |
Idec Pharmaceuticals Corporation |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
|
ES2350687T3
(es)
|
2002-07-03 |
2011-01-26 |
Ono Pharmaceutical Co., Ltd. |
Composiciones de inmunopotenciación.
|
|
US20110020273A1
(en)
*
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
|
WO2006004959A2
(en)
*
|
2004-06-30 |
2006-01-12 |
Egen Corporation |
Pegylated interferon alpha-1b
|
|
CA2585549A1
(en)
|
2004-11-18 |
2006-05-26 |
Vib Vzw |
Novel type leptin receptor antagonist
|
|
WO2006115800A2
(en)
|
2005-04-15 |
2006-11-02 |
The Regents Of The University Of California |
Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
|
|
EP1877434A2
(en)
|
2005-05-04 |
2008-01-16 |
Nautilus Biotech |
Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
|
|
US20080038224A1
(en)
|
2006-03-28 |
2008-02-14 |
Thierry Guyon |
Modified interferon-beta (IFN-beta) polypeptides
|
|
WO2008014612A1
(en)
|
2006-08-02 |
2008-02-07 |
Mcgill University |
Fusion proteins and methods for modulation of immune response
|
|
EP2102241A2
(en)
|
2006-12-15 |
2009-09-23 |
Ablynx N.V. |
Amino acid sequences that modulate the interaction between cells of the immune system
|
|
US11535673B2
(en)
|
2007-04-05 |
2022-12-27 |
President and Fellows of Harvard CoHege |
Chimeric activators: quantitatively designed protein therapeutics and uses thereof
|
|
US20110038865A1
(en)
|
2007-06-26 |
2011-02-17 |
University Of Miami |
Antibody- endostatin fusion protein and its variants
|
|
ES2536772T3
(es)
|
2007-09-21 |
2015-05-28 |
The Regents Of The University Of California |
El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
|
|
CN101525381B
(zh)
|
2008-03-04 |
2012-04-18 |
北京百川飞虹生物科技有限公司 |
一种重组复合干扰素及其表达载体的构建和表达
|
|
WO2010030671A1
(en)
|
2008-09-09 |
2010-03-18 |
University Of Medicine And Dentistry Of New Jersey |
Type i interferon antagonists
|
|
US8334101B2
(en)
|
2008-09-26 |
2012-12-18 |
University Of Massachusetts |
Intracellular DNA receptor
|
|
JP2012510806A
(ja)
|
2008-12-08 |
2012-05-17 |
コンプリクス エン ヴェー |
単鎖逆平行コイルドコイルタンパク質
|
|
WO2011017160A1
(en)
*
|
2009-07-28 |
2011-02-10 |
Pestka Biomedical Laboratories, Inc. |
Mutant human interferon proteins and genes
|
|
ES2534085T3
(es)
|
2009-08-17 |
2015-04-17 |
Roche Glycart Ag |
Inmunoconjugados dirigidos
|
|
US20130115189A1
(en)
|
2009-09-10 |
2013-05-09 |
Cytos Biotechnology Ag |
Use of Interleukin-1 Beta Mutein Conjugates in the Treatment of Diabetes
|
|
EP2343081A1
(en)
|
2009-12-31 |
2011-07-13 |
Rijksuniversiteit Groningen |
Interferon analogs
|
|
EP2718457A4
(en)
|
2011-06-06 |
2014-12-24 |
Immungene Inc |
GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT
|
|
SG10201603411WA
(en)
|
2011-10-28 |
2016-07-28 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
CN104245734B
(zh)
|
2012-01-20 |
2017-09-05 |
非营利性组织佛兰芒综合大学生物技术研究所 |
靶向突变体α‑螺旋束细胞因子
|
|
ES2800426T3
(es)
|
2012-03-03 |
2020-12-30 |
Immungene Inc |
Moléculas de fusión anticuerpos-mutante de interferón modificadas
|
|
RS60280B1
(sr)
|
2013-03-12 |
2020-06-30 |
Molecular Templates Inc |
Citotoksični proteini koji sadrže ciljane vezujuće regione za ćelije i regioni shiga toksina a podjedinice za selektivno ubijanje određenih vrsta ćelija
|
|
CN103319608B
(zh)
|
2013-07-01 |
2014-08-27 |
江苏众红生物工程创药研究院有限公司 |
猪IFNɑ1-Fc融合蛋白及其编码基因和表达方法
|
|
WO2015007536A2
(en)
|
2013-07-18 |
2015-01-22 |
Vib Vzw |
Fusokines involving cytokines with strongly reduced receptor binding affinities
|
|
JP6595988B2
(ja)
|
2013-07-19 |
2019-10-23 |
ヴィブ ブイゼットダブリュー |
ターゲットされる修飾ｔｎｆファミリーメンバー
|
|
CA2918119C
(en)
|
2013-07-19 |
2022-11-29 |
Centre Hospitalier Regional Universitaire De Montpellier |
Targeting of ifn.alpha.2 antagonists to treat autoimmune diseases
|
|
DK3022226T3
(en)
|
2013-07-19 |
2019-03-25 |
Vib Vzw |
TARGETED MODIFIED IL-1 FAMILY MEMBERS
|
|
US11702477B2
(en)
|
2015-11-06 |
2023-07-18 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
|
US11001631B2
(en)
*
|
2016-02-05 |
2021-05-11 |
Orionis Biosciences BV |
Clec9A binding agents
|
|
US11248057B2
(en)
|
2016-03-07 |
2022-02-15 |
Vib Vzw |
CD20 binding single domain antibodies
|
|
CA3017813C
(en)
|
2016-03-17 |
2021-12-07 |
Oslo Universitetssykehus Hf |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
|
WO2017194783A1
(en)
*
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Targeted mutant interferon-beta and uses thereof
|
|
CN109563141A
(zh)
|
2016-05-13 |
2019-04-02 |
奥里尼斯生物科学公司 |
对非细胞结构的治疗性靶向
|
|
CA3040802A1
(en)
*
|
2016-10-24 |
2018-05-03 |
Orionis Biosciences Nv |
Targeted mutant interferon-gamma and uses thereof
|
|
EP3577133A1
(en)
|
2017-02-06 |
2019-12-11 |
Orionis Biosciences NV |
Targeted chimeric proteins and uses thereof
|
|
CN110573172A
(zh)
|
2017-02-06 |
2019-12-13 |
奥里尼斯生物科学有限公司 |
靶向的工程化干扰素及其用途
|
|
EP3580230B1
(en)
|
2017-02-07 |
2026-04-22 |
Vib Vzw |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
|
EP3665201A4
(en)
|
2017-08-09 |
2021-06-02 |
Orionis Biosciences, Inc. |
CD8 BINDERS
|
|
US12091463B2
(en)
|
2017-08-09 |
2024-09-17 |
Orionis Biosciences, Inc. |
Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)
|
|
JP7423511B2
(ja)
|
2017-08-09 |
2024-01-29 |
オリオンズ バイオサイエンス インコーポレイテッド |
Ｐｄ－１およびｐｄ－ｌ１結合物質
|
|
US20200354424A1
(en)
|
2018-01-26 |
2020-11-12 |
Orionis Biosciences, Inc. |
Xcr1 binding agents and uses thereof
|
|
JP2021513361A
(ja)
|
2018-02-05 |
2021-05-27 |
オリオニス バイオサイエンシーズ，インコーポレイテッド |
線維芽細胞結合物質およびその使用
|
|
US20210024631A1
(en)
|
2018-03-28 |
2021-01-28 |
Orionis Biosciences, Inc. |
Bi-functional proteins and construction thereof
|
|
WO2020033646A1
(en)
|
2018-08-08 |
2020-02-13 |
Orionis Biosciences, Inc. |
SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
|
|
US12410225B2
(en)
|
2018-11-08 |
2025-09-09 |
Orionis Biosciences, Inc |
Modulation of dendritic cell lineages
|
|
CA3125527A1
(en)
|
2018-12-20 |
2020-06-25 |
Orionis Biosciences, Inc. |
Particle based small molecule-protein complex trap
|
|
JP7729778B2
(ja)
*
|
2019-03-28 |
2025-08-26 |
オリオニス バイオサイエンシズ，インコーポレイテッド |
Ｆｍｓ様チロシンキナーゼ３（ｆｌｔ３）に対するキメラタンパク質およびキメラタンパク質複合体
|
|
JP7689079B2
(ja)
*
|
2019-03-28 |
2025-06-05 |
オリオニス バイオサイエンシズ，インコーポレイテッド |
治療用インターフェロンアルファ１タンパク質
|